Last reviewed · How we verify
NCT06986434
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
EARLY_PHASE1 trial testing CAR19BCMA-T cells in Relapsed or Refractory Plasma Cell Neoplasms in 20 participants. Not yet recruiting.
22 May 2027
Quick facts
| Lead sponsor | Affiliated Hospital to Academy of Military Medical Sciences |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 2 April 2026 |
| Primary completion | 22 May 2027 |
| Estimated completion | 25 August 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- CAR19BCMA-T cells
- fludarabine and cyclophosphamide — full drug profile →
Conditions studied
- Relapsed or Refractory Plasma Cell Neoplasms — all drugs for Relapsed or Refractory Plasma Cell Neoplasms →
- Lymphomas/Leukemias With Plasmacytic Differentiation — all drugs for Lymphomas/Leukemias With Plasmacytic Differentiation →
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Who can join
Adults 18 to 75, any sex, with Relapsed or Refractory Plasma Cell Neoplasms or Lymphomas/Leukemias With Plasmacytic Differentiation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Verify or expand the search:
- PubMed search for NCT06986434
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAR19BCMA-T cells
Trials testing the same drug.
- NCT07077330 — CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms · EARLY_PHASE1 · not yet recruiting
Other Affiliated Hospital to Academy of Military Medical Sciences trials
Trials by the same sponsor.
- NCT07416682 — CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms · EARLY_PHASE1 · not yet recruiting
- NCT06834529 — CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma · Phase 1, PHASE2 · recruiting
- NCT06152263 — LCI in Chronic Atrophic Gastritis and Early Gastric Cancer · unknown
- NCT05645601 — CAR-NK Targeted CD19 for r/r B-cell Malignancies · Phase 1 · unknown
- NCT05574608 — Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06986434 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital to Academy of Military Medical Sciences
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06986434.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing